Drug intelligence / Profile preview

rdGCM-103

Development stage: Preclinical
Lead developer: Gencellmed
Modality: Gene Therapies
Administration: Intraarticular

Overview

rdGCM-103 is a preclinical-stage gene therapy candidate being developed by Gencellmed for the treatment of osteoarthritis. The therapeutic utilizes a replication-defective Herpes Simplex Virus type 1 (HSV-1) viral vector platform. This vector is engineered to be non-replicating to ensure safety while leveraging the virus's natural ability to efficiently transduce cells and maintain long-term transgene expression within the joint environment. The specific therapeutic gene and molecular target delivered by rdGCM-103 have not been publicly disclosed by the developer.

Beyond the preview

Go deeper on rdGCM-103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rdGCM-103.

Explore the full profile